NBE July 22, 2020

Novartis launches first-of-its-kind not-for-profit portfolio of medicines for symptomatic treatment of COVID-19, the company said. The new initiative of Novartis aims to help patients in low-income and lower-middle-income countries (LIC; LMIC) access affordable medicines to treat the major symptoms of COVID-19 – a critical need in the absence of a vaccine or curative treatment.

newbusinessethiopia March 19, 2020

Leishmaniasis patients in Eastern Africa may soon benefit from a new drug set to be developed by collaboration of Novartis, one of the biggest pharmaceuticals company and the Drugs for Neglected Diseases initiative (DNDi), a not-for-profit research and development organization.